Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
Status:
Completed
Trial end date:
2021-06-11
Target enrollment:
Participant gender:
Summary
Aim of this study is to provide the "proof of concept" of efficacy and tolerability of
lurbinectedin monotherapy in progressive malignant mesotheliomas.